Epidermal growth factor receptor mutations in non-small cell lung cancer patients from a single institution in Vietnam
Main Article Content
Keywords
Tóm tắt
Objective: The purpose of this study was to evaluate the epidermal growth factor receptor (EGFR) mutations and relationship with some clinical, paraclinical characteristics in non-small cell lung cancer (NSCLC) patients in 108 Military Central Hospital, Vietnam. Subject and method: This is a prospective study. Tumor tissue samples were collected from 500 NSCLC patients from Jan 2015 to Jan 2018. DNA was extracted from tissue samples and examined for EGFR mutations by a peptide nucleic acid (PNA)-locked nucleic acid (LNA) polymerase chain reaction (PCR) clamp-based detection test. Result: The patient’s mean age was 63.02 ± 9.6 years old and male/female ratio was near 4/1. Histology showed 80% of adenocarcinoma, 3.6% of squamous cell carcinoma, 0.8% of large cell carcinoma, 0.2% of adeno-squamous cell carcinoma, and 15.4% of NSCLC undefined type. In total, 35.6% were positive for presence of EGFR mutations. EGFR mutations were observed 2.2% in exon 18, 61.2% in exon 19, 34.8% in exon 21, and 1.7% in exons 20 and 21. EGFR mutations by histology were 38.2% in adenocarcinoma and 25% in other histologic types (p<0.05). EGFR mutations by demographic were 55.1% in female and 30.3% in male (p<0.05) and 44.8% in non-smoker and 30.3% in smoker (p<0.05). Conclusion: The mutation rate of EGFR in NSCLC in our hospital was 35.6%. The EGFR mutation rates were higher in adenocarcinoma vs other histologic types, in female vs male, and in non-smoker vs smoker. Their differences were statistically significant.
Keywords: EGFR mutations, non-small cell lung cancer.
Article Details
Các tài liệu tham khảo
2. Mai Trong Khoa, Tran Dinh Ha, Pham Cam Phuong et al (2016) The determination of EGFR mutations in the non-small cell lung cancer patients in Bach Mai Hospital. Journal of Vietnamese Oncology: 235-242.
3. Pierre P Massion, Lecia V Sequist, William Pao (2015) Biology of lung cancer. Textbook res-piratory medicine. Sixth edition 2: 912-925.
4. NCCN (2018) Guideline insights, non-small cell lung cancer. Feature updates to the NCCN Guidelines.
5. Markus D Siegelin and Alain C Borczuk (2014) Epidermal growth factor receptor mutations in lung adenocarcinoma. Laboratory invertigation 94: 129-137.
6. Lindeman NI, Cagle PT, Beasley MB, et al (2013) Molecular testing guideline for selec-tion of lung cancer patient for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, Internation-al Association for Molecular Pathology. J MolDiagn 15: 415-453.
7. Dacic S (2008) EGFR assay in lung cancer. AdvAnatPathol 15: 241-247.
8. Yuankai Shi, Joseph Siu-Kie Au, Sumitra Thongprasert et al (2014) A prospective, mo-lecular epidemiology study of EGFR mutations in Asian patients with advanced non-small cell lung cancer of adenocarcinoma hiaatology (PIONEER). Journal of Thoracic Oncology 9(2): 154-162.